Suppr超能文献

新一代酪氨酸激酶抑制剂相关无症状性脑血管狭窄:两例说明性病例。

New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases.

机构信息

Department of Neurosurgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

出版信息

Acta Neurochir (Wien). 2022 Jun;164(6):1623-1626. doi: 10.1007/s00701-021-05043-3. Epub 2021 Nov 26.

Abstract

New-generation tyrosine kinase inhibitors (TKIs), nilotinib and ponatinib, for chronic myelogenous leukemia (CML) have been reported to cause symptomatic cerebral ischemia. Herein, we report two patients with asymptomatic cerebral artery stenosis associated with these TKIs, as a previously unreported finding. Both patients were in their 40 s and administered new-generation TKIs without vascular risk factors. New-generation TKIs for CML can cause major cerebrovascular stenosis without any symptoms. Examining the neck and intracranial arteries using magnetic resonance angiography and carotid ultrasonography may prevent future cerebral infarctions associated with these TKIs.

摘要

新型酪氨酸激酶抑制剂(TKI)尼洛替尼和达沙替尼治疗慢性髓性白血病(CML)可引起症状性脑缺血。在此,我们报告两例新型 TKI 治疗相关无症状性颅内动脉狭窄患者,这是一种以前未报道的发现。两例患者均为 40 多岁,无血管危险因素,应用新型 TKI 治疗 CML。新型 TKI 治疗 CML 可导致无任何症状的大血管狭窄。使用磁共振血管造影和颈动脉超声检查颈部和颅内血管可能预防与这些 TKI 相关的未来脑梗死。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验